This Stock Will Double In The Next 18 Months...

Our Guarantee: If it Doesn't We'll Give You $5,000 in Stansberry Credit

(Limited to only 500 readers)

Dear Stansberry Research Subscriber,

My name is Brett Aitken. I'm a Managing Director and Senior Analyst for Stansberry Research.

I'm writing you today to tell you about an immediate and urgent opportunity which we believe can double your money in the next 18 months.

And we're putting our money where our mouth is – by allowing you to get full Stansberry Credit for every dollar you spend on this research, if the stock doesn't double in the time we expect.

You might think this is an outrageous, even foolish offer.

After all, we can't predict the future.

So we’re limiting this offer to just 500 readers. Once we fill these 500 spots, we’ll remove this offer, and may never make it again.

In the past, we’ve filled 500 spots on similar offers in a matter of hours.

Which means you'll need to act prudently, but also swiftly if you are interested.

In fact, we could already be near our limit as you read this. It wouldn’t surprise me if we close the doors on this offer in less than a few days from now.

So I'll get straight to the point...

Let me explain why we're making this historic offer for the first time in our 19-year history. And why we are combining it with the most generous offer I've ever seen us make.

Here's the full story...

The most valuable pill in development, anywhere

in the world

In short, our team believes a tiny biotech company most people have never heard of will soon announce positive trial data for an experimental treatment, which tens of millions of Americans desperately need.

Based on developments over the past several weeks, we expect the announcement will lead to nationwide approval of the company's treatment, and will make their patents among the most valuable in the entire pharmaceutical universe.

Dave Lashmet, editor of our elite research service Stansberry Venture Technology, has been following this story closely for the past four years.

If you aren't familiar with Dave's work, he is the most successful biotech analyst in the financial world, in our experience.

Since November 2014, he has made 42 recommendations. So far, 13 have doubled or more. In other words, almost one in every three of his recommendations have gone up 100% or more.

And looking at his current portfolio, my bet is that more are on the way, including the one I'm talking about today.

For example, just last week, Dave got another big call right. A company he has followed for years that is developing a treatment for Alzheimer's announced news that sent the shares soaring by more than 40% in a single day.

These stories are becoming common for Dave's readers.

Not surprising, considering he travels and attends more conferences than any analyst on our team. He reads journals, trial data, and research papers that few other analysts bother with.

He's been to conferences and visited labs at Harvard Medical School, met with professors at Johns Hopkins, sat in on lectures and toured the facilities at MIT... has invented several high-tech patents... and even met with a U.S. Congressional delegation.

And the effort has been well worth it...

Dave is the only analyst I know who has written about dozens of experimental treatments and technologies in the early 2000s long before Wall Street paid them any serious attention.

For instance...

• Dave first wrote about ID Biomedical (IDBE) at less than $7 a share. (It was bought out for more $35 a few years later).

• He also wrote about Regeneron Pharmaceuticals (REGN) for less than $20 per share. Today it trades for about $365 a share.

Just in Dave's first few years working here, he identified time and time again what became the most important biotech stories of the next two decades.

• For example, Dave first wrote about vaccine maker Crucell (CRXL) in his letter back in 2004. The stock went up 375% before the company was bought out.

• Another drug company, Alnylam (ALNY), eventually rose as much as 645% after Dave first covered it.

• Autonomy Corp. (AU.L), a high-tech data firm, went up 797% after Dave's initial write-up.

So when I received an email from Dave recently with the words, “hottest pick” in the subject line, I opened it immediately.

But what he said got us most excited of all...

You see, the treatment Dave has uncovered – currently in Phase III trials – may soon help prevent the #1 cause of death in the United States.

A disease that currently accounts for one out of every four deaths in our country.

We’re talking about 56 million Americans who could be healthier and happier by taking a single pill – which could soon receive FDA approval.

As soon as next month, new data from this treatment’s ongoing trial could cement a new era of hope for the tens of millions of Americans who can potentially benefit from this treatment. And for investors, it could mean a windfall...

That’s because this particular treatment in development is one of the most lucrative types of medicine in the biotech world.

A similar drug produced by Merck hit sales of $2.6 billion per year in 2014...

Another comparable medicine made by AstraZeneca hit sales of $6.5 billion in 2011...

And Pfizer's offering in this space reached sales of $12.9 billion in 2006.

Yet today, the company we recommend you invest in right now has a market capitalization of only $1 billion.

In other words, once this drug’s final clinical trial results are announced, beginning next month, the pill this tiny company is developing could be worth sales of $10 billion per year... more than TEN TIMES higher than the entire value of the company.

And the story gets even better...

According to Dave, most drugs in this class have the negative side effect of causing muscular weakness. As a result, 40% of folks who are prescribed this type of drug don't stay on them for very long.

But with the radical new pill Dave has discovered, those side effects could be totally removed for the first time ever.

That's why if this tiny firm receives approval for their new treatment, it could be worth more than $10 billion or even $12 billion per year in sales...

In fact, it could become the highest selling drug of its kind in history.

Because according to an editorial piece in the Journal of the American Medical Association total sales of this kind of drug are still climbing...

In fact, sales could approach $1 trillion worldwide by 2020.

And the new treatment Dave has uncovered has the potential to become the number one product for this massive global market.

Which is one reason why – for the first time – our company is making an offer that seems outrageous...

Get in before next month's announcement

You see, Dave recently got his hands on trial data from this little-known company.

And the details inside have led us to a rare, incredibly convincing case for where this company is going, and why it could double your money in the next 18 months.

Thanks to this information, we now know this little-known firm will announce the first of two remaining pivotal Phase 3 results next month.

If the results are positive, as we expect, you want to be invested in the company BEFORE that announcement.

Few things can make you richer in the biotech world than buying into a little-known company just before it releases positive clinical data...

• Take Celgene (CELG), for example.

• In 2004, this New Jersey biopharmaceutical company made a breakthrough in diseased blood treatment. If you'd invested just $500 before its approval, you'd be sitting on over $7,000 today. A 1,400% gain.

• Or consider Incyte (INCY)...

• In 2011, this biotech firm in Delaware discovered a new treatment for high-risk myelofibrosis, a rare blood disease. You'd have over a 400% gain today if you'd invested before their breakthrough was approved.

Well... we believe the opportunity we're sharing today could prove just as lucrative, and become a household name in its form of treatment.

In fact, a second round of trial data will be released by this company in September as well, at which point, the stock could soar.

But by then, much of the opportunity may be gone.

Which is why we believe you NEED to get into this position TODAY.

As Dave wrote in his email to me, “Two phase III trials are complete. If the other two are successful, this stock is a Grand Slam.”

The last time Dave felt this strongly, we heard from Fred and Joyce M., who got into his recommendation and said, “Our annualized return exceeds 430%. To say we are happy with our initial trade is an understatement.”

Not to mention James R. who told us, “I pocketed about $11,000 in three days!”

In other words, Dave's newest recommendation could double before October if the data this tiny firm announces is positive.

And frankly, it could soar even higher over the long run.

Which is also why we are making this historic offer, today, for just 500 PEOPLE ONLY.

Three potential outcomes

You see, given the data so far, our view is that the drug works. But there are some side effects. So the FDA needs more data to determine the drug's safety risks. We believe this stock could easily double if both the upcoming trial announcements in August and September are positive.

But please remember, we don't have a crystal ball...

There are three potential outcomes for how we see this playing out...

OUTCOME #1: If both rounds of test results are positive, the stock will jump likely 100% or more in the next two months.

According to the company, at that point they will file for FDA approval in early 2019.

The approval process can take 5 to 8 months, so this treatment may not hit the market until the end of 2019, or later.

In other words, we have a roughly 18 month timeline until we'll know with certainty if the FDA will approve this treatment or not. Potentially, a little longer.

However, the reality is that we expect this tiny firm will become an acquisition target at some point if the data revealed over the next two months is positive... for a simple reason.

The company is too small to bring such a blockbuster drug to market on their own. It would need to build manufacturing facilities, hire and train thousands of sales representatives, and send these reps out into hospitals to sell its product...

Of course, an acquisition could also wait for this new treatment to receive official approval from the FDA.

This treatment stands to become a blockbuster drug, and Big Pharma knows that. For them, it makes more sense to wait for the positive trials and pay $2 billion or more for the company, than pay $1 billion for it today, before the trials are complete.

And therein lies the opportunity for the biggest gains.

In other words, if everything goes well, this firm will need to partner with another company or be purchased by a larger company to bring this drug to market.

But either way, the drug should hit shelves in the next two years, and we believe investors will make a killing if they buy this company and hold it for the next 18 months. But ONLY if you get in now, before the first announcements.

OUTCOME #2: The second way this could play out would be a “mixed bag” result...

In other words, if one of the two upcoming trials is positive, and the other is negative, the market won't get excited and the stock won't double by October.

Instead, were this to happen, we expect the share price to remain about where it is today for the next 18 months.

If this happens, you may make a little or lose a little on whatever you put into the stock. We'll give you a credit for every dollar you spent to apply to any other research or product we offer.

And the upside is that you'll still receive Dave Lashmet's Stansberry Venture Technology (our most sophisticated research letter) for the next 18 months.

So you’ll essentially be getting the most valuable research we offer, a full 18 issues, where he’ll give you exciting opportunities to make venture capital-like returns on some of the smallest and most explosive investments in the market. And remember, nearly one in three of Dave's recommendations have doubled or more over the past three years.

OUTCOME #3: Now, the third potential outcome is what I consider the “worst case scenario.”

The worst case scenario is that both upcoming trials reveal terrible data.

If that happens, this stock could realistically go to zero by October.

So let me be clear: if the idea of losing money on this opportunity scares you, PLEASE don't get in. No investments are guaranteed.

We only have 500 spots for this offer.

We know that not everyone has an appetite for risk, and that's fine.

But if you are someone who wants to hear about our favorite idea for a short-term speculation with tremendous upside, then I urge you to start with a small position.

After all, with the offer we are making today, the only money you are risking is what you put directly into the investment. If the situation doesn't pan out like we think it will, you can roll the money you invested in this research into any other subscription or product we offer.

Better yet, you'll get 18 months of our most elite research service, Stansberry Venture Technology for essentially free if we are wrong.

You'll be entitled to a full 18 months of Stansberry Venture Technology issues, including the full model portfolio and access to all 30+ current recommendations, along with each new recommendation Dave makes over the next 18 months.

In other words, we have structured this offer in a way that you have almost nothing to lose on our research, and a tremendous amount to gain by taking us up on this opportunity today.

But again, we’re ONLY making this offer available to 500 people. Once we fill those spots, we absolutely must remove this offer. So unless you act now, I cannot guarantee your spot.

We know that this tiny company likely won't receive official FDA approval for their experimental treatment for 18 months - no matter how good the trial results are that will be announced in August, and September.

By the time the company receives FDA approval, this treatment could be well on its way to being widely recognized as a potential $10 billion a year drug. And the opportunity I'm telling you about today will be gone.

Our offer will allow a full 18 months for the situation to play out.

Of course, it could all play out in just a matter of weeks too – if the results announced over the next two months are as positive as we anticipate.

We believe this new treatment is the most valuable pill in development anywhere in the world.

But whether we're right or wrong, you'll receive Stansberry Venture Technology, for the next 18 months, as part of this offer.

In Stansberry Venture Technology, Dave covers investments with the potential to make multiple times your money on venture capital-like investments most of Wall Street knows little or nothing about.

Frankly, it's the most valuable research we publish.

For example, at this exact same time last year, Dave recommended a tiny company with a targeted cancer treatment that is currently up 119%. More than double your money.

His model portfolio includes open positions like:

• 140% gains on the maker of a heart medication.
• 136% gains on small radiation therapy company.
• 101% gains on a photon-beam treatment company.
• 92% gains on an immunotherapy start up.
• 120% gains on brain cancer drug company.
• 143% gains on a video game company.
• 263% gains on a drug for postpartum depression.
• 454% gains on a graphics processing company.

Bottom-line: Dave has a knack for finding situations where a single announcement results in the stock skyrocketing.

And while we can't guarantee his newest recommendation will double, you're almost certain to see huge gains if you have access to Dave's research, his entire portfolio of open recommendations, and every new recommendation he makes over the next 18 months.

And frankly, there's no better place to make huge gains in the market right now than sectors like high tech and biotechnology.

Let me explain...

Biotech is Booming

You see, while most of the market has been languishing in 2018, biotechnology investments have been steadily climbing...

Over the last 30 months, the sector as a whole has risen by roughly 100%.

In other words, you could have made great gains by simply buying the index.

Individual companies have done even better...

For example, Mirati Pharmaceuticals is up 58% over the last three months. And in the last year, it soared 1,180%.

RegenexBIO soared 35% in the last month, for a total of nearly 300% gains in the last year.

Arrowhead Pharmaceuticals is up 127% in the last quarter, for a 950% total gain over the trailing 12 months!

In other words, despite the fact that the overall market, as measured by the S&P 500, has essentially gone nowhere since the beginning of 2018...

Dave is still consistently recommending biotechnology stocks that double and even triple, very quickly.

And by and large, the best way to make money from these kind of situations is to buy these tiny drug companies just before they release positive data about their clinical trials.

For example in September, Endocyte, Inc. (ECYT) announced regulatory approval for one of their experimental treatments, and the stock rocketed 366%.

Not long after, Zogenix, Inc. (ZGNX) made a similar announcement about the results from a Phase III trial on a drug that treats Dravet syndrome, a form of childhood epilepsy.

The stock soared over 250%.

This May, Madrigal Pharmaceuticals (MDGL) announced positive Phase II data for its non-alcoholic Steatohepatitis treatment and the stock tripled – a 200% gain overnight...

And just a few weeks ago, on June 21, NanoBiotix (NANO.FP) announced positive Phase II/III topline data...

And the stock immediately shot up 64% in a single day!

In short, one of the fastest ways to make multiple times your money in a short period of time is to invest in tiny biotech firms just before they announce positive trial data.

And nobody we know in the biotech world does this better than Dave Lashmet.

I've travelled with Dave on research trips across three continents including places in New Zealand, Spain and across the U.S.

We've attended conferences for cancer research in Texas, radiology in Chicago, and earlier this year we went to Barcelona for the Mobile World Congress.

Dave loves to track down great investment ideas where no one else is looking.

I've seen him chase down company executives in the hallways at conferences. He talks to everyone. In front of hundreds of people, I've seen him ask the most probing and difficult questions to professors, surgeons, scientists, engineers, and CEO's during their presentations.

And, by the way, it isn't only Dave Lashmet and our team who are bullish on this sector right now.

Analyst Steve Sjuggerud has famously said that, “If you can catch just one good bull market in biotechnology, you may never need to work again.”

Steve turned bullish on the sector in August last year and still has a “BUY” rating for the sector in his portfolio.

And that's why we're going one step further...

Our Most Elite Research

You see, as Porter Stansberry once said:

"Almost anybody can give you a biotech stock that's going to double or triple. That's not hard to do...

But it's VERY hard to find someone who can find stocks that rise 300%... 500%... even more than 1,000%, as often as Dave does."

That's why we have an entire research service devoted to Dave Lashmet and his top recommendations.

It is also why it's the most sophisticated (and also expensive) research we offer.

You see, Dave doesn't waste time looking for big companies with popular technologies.

Instead, he finds small, early-stage companies with the potential to grow 500% to 1,000%, or more, which he only shares with the small, elite group of readers in his letter, Stansberry Venture Technology.

One time, Dave got us into a backroom meeting with the engineers of a major tech firm that showed us a prototype for a future project. Dave travels thousands of miles to interview industry experts including eye doctors, heart surgeons, and even rocket scientists.

We've spent millions of dollars supporting his research efforts. And it's worth every penny.

However, Stansberry Venture Technology may not be right for you.

The investment opportunities we'll be sharing are best suited for only the most serious and sophisticated investors.

Unlike most of our newsletters, you can't simply go to our website right now and sign up for details on how to take advantage of this opportunity.

The ONLY way to become a member today is to take us up on this offer.

And the FASTEST way to do that is to call our Member Services team today:

1-800-439-5059

Our friendly Baltimore-based team will walk you through the offer.

If you call in now, and decide to join Stansberry Venture Technology today - we'll instantly e-mail you a copy of our urgent buy recommendation of this company: "The Most Valuable Pill In Development Anywhere in the World."

This report includes even more details than I have the space to share with you here.

And it gives you the company's name, ticker symbol, and a buy-below price... so you can establish a position immediately.

But no matter how generous an offer, or how foolish a guarantee we give you, I estimate less than 1 in 1000 readers will even consider following Dave's work.

You see, Venture Technology is best suited for you if you love early-stage opportunities... are curious about the future of our society... and the best investments along the way...

Folks like subscriber Ron M., who recently told us he's up about $31,000.

But Dave's not interested in "tire-kickers"... who don't like to speculate and aren't willing to understand his research.

Over the past 30 years, I've worked with engineers, researchers, finance and high-level executives across three continents. I've travelled to more than 30 countries and done business in more than a dozen of them. I've not seen anyone from any country, in any language, do research like Dave. And I have never seen anyone hit so many triple digit winners... so consistently.

That's what makes Venture Technology the most elite research we offer.

It's also why one full year of Venture Technology normally costs $5,000.

If that sounds like too much money, I'm sorry. This isn't for you.

The reality is, Venture Technology is a steal at $5,000 a year.

As subscriber Rick V. said, “I got my subscription back within a month of so.”

But even though this research is a steal at the normal price...

We're doing something for the first time ever today, offering you a $5,000 Stansberry credit guarantee... an offer you may never see again.

But you must take advantage of this deal now, if you're interested. 

The best way to get started is to call in today, and speak with one of our member services representatives, right now.

We'll answer any questions you have about this research service, or the guarantee we are offering you today

Just give us a call now at 1-800-439-5059.

You'll instantly be connected with one of our college-educated representatives based in our Baltimore office. (We don't route any of our calls to a call center overseas. Your call goes straight to our headquarters.)

If you're not happy with your conversation... hang up.  Total time commitment: 5 minutes or less.

Either way, there's very little you can lose, and whole lot to gain by taking advantage of our office and guarantee today.

We're putting our money where our mouth is...

If this company doesn’t double in the next 18 months, we’ll give you full credit for every dollar you spend today on Dave Lashmet’s Stansberry Venture Technology.

You can use it to extend your subscription to Stansberry Venture Technology, pay maintenance fees or to purchase any of our other products... you can apply it toward a Stansberry Choice, or Stansberry Alliance membership.

In short – we’re making the most generous offer in our 19-year history to encourage you to take advantage of this rare opportunity.

The price is $5,000 for a year. But through this special offer, you'll receive 6 FREE bonus months. Plus, you're protected by the most generous promise we've ever made...

If things don’t turn out as we believe, we’ll give you a credit for $5,000.

Remember, we believe there’s no reason you need to put a lot of money into this idea.

We urge you to start with a small stake.

And no matter what... over the next 18 months, you’ll continue to receive monthly issues from our most valuable research service, Stansberry Venture Technology.

But we also know that if this new treatment doesn’t get approval from the FDA, you could lose the money you invest on this position. If you can’t afford to lose the entire amount you invest in this stock, DO NOT buy it. This is NOT for the rent money.

So we are limiting the chance to discover this opportunity to the first 500 people who respond.

For better or worse, once we fill these spots, NOBODY else will be allowed to get this offer.

So if you’re interested, you must decide right now if you are in... or out.

Click here to see a summary of this offer, the historic offer we are making, and everything else you need to know to make your purchase.

Regards,

Brett Aitken
Managing Director

P.S. Remember, we’re opening just 500 spots for what could be the best-performing new stock recommendation we’ve made all year. So if you're even the slightest bit interested, I urge you to take a few minutes to call us today, before this offer closes.

1-800-439-5059

P.P.S. And don't forget...

I've arranged for you to receive a one-time-only $5,000 credit guarantee if you take advantage of this offer today.

This is your only shot to get the full details of this unique opportunity before this company's drug announcement is made... at which point, I expect this experimental treatment to become one of the biggest stories in the medical world.

Along the way, this small biotech stock could double your money or more.

So if you're interested... give us a call now... and we'll send you the details on this timely opportunity today, along with a $5,000 credit guarantee.

We look forward to speaking with you.

Call Now:

1-800-439-5059